Volcano Corporation (NSDQ:VOLC) and Boston Scientific (NYSE:BSX) announced a new, cosponsored Syntax study to test precision in stent placement.
The companies announced the upcoming study at the EuroPCR annual meeting in Paris, France.
Guided percutaneous coronary intervention with appropriate stent placement can be an alternative to coronary bypass surgery for some patients.
For the Syntax 2 study, Volcano’s iFR/FFR Hybrid software will measure blood vessels in patients to determine which lesions should be treated. The study will use Boston Scientific’s Synergy DES, and will use IVUS devices from both companies for accurate placement, compared to agiography alone.
"The Syntax 2 study will use a new ‘clinical Syntax score’ to first identify prospective patients we believe will benefit from a less-invasive PCI procedure, and then use physiology and IVUS guidance along with the modern-day drug-eluting stent technology," said Patrick Serruys of the Erasmus Medical Center in Rotterdam, Netherlands, in prepared remarks.
"The goal is to show that delivering the most precise and modern-day PCI possible will allow more patients to be treated with this excellent alternative to bypass surgery."
Volcano also unveiled preliminary findings supporting its Instant Wave Free Ratio Software at EuroPCR.
